IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV program-driven stock growth.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce ...

Dario Scimeca, General Counsel and Secretary of Precision BioSciences Inc . (NASDAQ:DTIL), a biotechnology company with a market capitalization of $38 million and currently trading at $4.97, executed ...

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL – Free Report) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports ...

The filing also noted Smith's indirect ownership of 7,931 shares through a Charitable Remainder Unitrust. The company's market capitalization stands at $38.08 million, with a P/E ratio of 3.28, ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating today.Stay Ahead of the ...

Precision BioSciences Inc (DTIL) stock saw a modest uptick, ending the day at $5.7 which represents a slight increase of $1.20 or 26.67% from the prior close of $4.5. The stock opened at $6.8 and ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $30.00. Discover outperforming stocks and invest smarter ...

CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the ...

(RTTNews) - Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Thursday, announced positive clinical efficacy data from its partner iECURE in the Phase 1/2 OTC-HOPE ...